Fang FM, et al. - Researchers examined 68 patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT) for the toxicity, changes of quality of life (QOL), and survival. The patients displayed 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates of 97.0%, 86.4%, 82.0%, and 88.1%, respectively. Outcomes revealed attainment of excellent locoregional control with few severe late toxicity, and good general health status using CCRT with SIB-VMAT in NPC patients.